LivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says

MT Newswires Live

2025/09/04

LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.

The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.

The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.

The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.

Needham has a buy rating and a $64 price target on LivaNova.

Shares of LivaNova were down 1.4% in recent trading.

Price: 56.10, Change: -0.82, Percent Change: -1.44

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564169023"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564169023\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564169023?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 03:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564169023","market":"us","top_or_hot":-1,"title":"LivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says","media":"MT Newswires Live","content":"<html><body><p> LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.</p><p>The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.</p><p>The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.</p><p>The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.</p><p>Needham has a buy rating and a $64 price target on LivaNova.</p><p>Shares of LivaNova were down 1.4% in recent trading.</p><p>Price: 56.10, Change: -0.82, Percent Change: -1.44</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-04 03:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.</p><p>The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.</p><p>The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.</p><p>The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.</p><p>Needham has a buy rating and a $64 price target on LivaNova.</p><p>Shares of LivaNova were down 1.4% in recent trading.</p><p>Price: 56.10, Change: -0.82, Percent Change: -1.44</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"醫療保健技術","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2564169023","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564169023","pubTimestamp":1756928654,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"LivaNova  could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.The device could capture market share from Inspire Medical , with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.Needham has a buy rating and a $64 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","INSP":"Inspire Medical Systems","LIVN":"LivaNova PLC","BK4082":"医疗保健设备"},"translate_title":"Needham表示，LivaNova睡眠呼吸暂停设备可能会从2026年起推动增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIVN":0.9,"INSP":0.9},"content_text":"LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.Needham has a buy rating and a $64 price target on LivaNova.Shares of LivaNova were down 1.4% in recent trading.Price: 56.10, Change: -0.82, Percent Change: -1.44","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}